September 29, 2017 09:45 AM EDT
Peer Review

Chris Car­pen­ter joins the R&D ex­o­dus out of phar­ma; George Church's eGe­n­e­sis se­lects Jodie Mor­ri­son as new CEO

Shehla Shakoor

Managing Director

⇨ Af­ter spend­ing the last decade in Big Phar­ma R&D, Chris Car­pen­ter is mak­ing the leap to biotech, join­ing the ris­ing star …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times